louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00588783: I-beam and Cruciate Tibial Components Used in Total Knee Replacement
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Degenerative Arthritis
Osteoarthritis
Rheumatoid Arthritis
Knee Arthritis
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
Collaborators: name: New Lexington Clinic
First posted: 2008-01-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include patients requiring total knee replacement.

Brief summary: The purpose of this study is to compare the clinical outcomes of using an I-beam or cruciate tibial component in total knee replacement.


Eligibility criteria: Inclusion Criteria:

* Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartment are involved.
* Patients requiring correction of varus, valgus, or posttraumatic deformity
* Patients requiring correction of revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Exclusion Criteria:

* Patients with infection, sepsis, or osteomyelitis.

Primary outcomes:
measure: Revision rate
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: United States
facility: Biomet Orthopedics, LLC
state: Indiana
Study officials:
References:
Clinical trial NCT00250783: Pre-Clinical Models in Gynecological Tumors A Tissue Repository
Official title: Pre-Clinical Models in Gynecological Tumors: A Tissue Repository
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Neoplasms
Uterine Neoplasms
Keywords: Corpus Uteri
Endometrium
Cancer
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2005-11-08
Enrollment: 26
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: tumor and normal tissues, ascites, and/or serum, and/or urine from women with malignant or premalignant gynecological conditions for which they are undergoing medically-indicated surgery, and normal tissues from women without malignancy who volunteer to donate serum and/or tissue at the time of medically indicated surgery.

Brief summary: The purpose of this study is to provide a repository for long-term storage of endometrial cancer tumor and normal tissue, ascites and serum. This material will be used in studies to better understand the molecular biology of endometrial cancer.

Detailed description: BACKGROUND AND RATIONALE

This protocol will create a central repository for banking tumor and other tissues as well as serum from patients with uterine corpus tumors. In addition, this protocol will also serve as a central repository for serum and tissue to healthy post-menopausal and peri-menopausal controls.

There will be an "internal" bank. The internal bank will have samples available to UNM investigators.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing hysterectomy, or who have endometrial cancer, and are under routine surveillance.
* Patients may have received prior hormonal, cytotoxic chemotherapy, irradiation or surgical therapy.
* Healthy post-menopausal and peri-menopausal women.
* A consent form must be signed by the patient prior to study entry.

Exclusion Criteria:

Study Patients:

* Patients who do not have primary uterine corpus tumors.
* Patients with less than one gram of tumor tissue available to procurement.

Controls:

* Patients unwilling to have their medical records reviewed for height, weight, and general medical history (see attached data sheets).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Harriet Smith, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03065283: Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women
Official title: Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Individuals
Lead sponsor: Universidade Federal do Ceara
Sponsor class: OTHER
First posted: 2017-02-27
Enrollment: 75
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The sample was randomly divided by electronic draw in two groups, the intervention group (GI), where two techniques were performed, one for diaphragmatic release and another for relaxation of the diaphragm pillars. In the control group (CG) the same techniques were applied, but in a placebo form.
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate the immediate effects of diaphragmatic release techniques on posterior chain flexibility and lumbar spine amplitude. Respiratory muscle strength and chest cavity mobility in healthy women.

Detailed description: The aim of this study was to evaluate the immediate effects of diaphragmatic release techniques on posterior chain flexibility and lumbar spine amplitude; Respiratory muscle strength and chest cavity mobility in healthy women. This is an intervention study with a randomized controlled trial design. The randomized study in two groups, the Intervention Group in which two diaphragmatic release techniques were performed and the Control Group where two placebo techniques were applied in 75 participants between 18 and 35 years of age. For intragroup analysis the paired Student t test was used, comparing the outcomes before and after the intervention and for intergroup analysis the independent Student t test.

Eligibility criteria: Inclusion Criteria:

* sedentary female participants
* aged between 18 and 35 years.

Exclusion Criteria:

* those with cardiovascular, respiratory obstructive or restrictive disease
* smokers and ex-smokers
* who were or were submitted to speech therapy less than a year ago
* those with postural deviation type scoliosis

Primary outcomes:
measure: Thoracic Mobility
timeFrame: baseline and immediately post-intervention
Secondary outcomes:
Other outcomes:
measure: Amplitude of Motion of the Lumbar Spine
timeFrame: baseline and immediately post-intervention
measure: Posterior Chain Flexibility
timeFrame: baseline and immediately post-intervention
measure: Maximum Respiratory Pressure
timeFrame: baseline and immediately post-intervention
Locations:
Study officials:
References:
citation: Marizeiro DF, Florencio ACL, Nunes ACL, Campos NG, Lima POP. Immediate effects of diaphragmatic myofascial release on the physical and functional outcomes in sedentary women: A randomized placebo-controlled trial. J Bodyw Mov Ther. 2018 Oct;22(4):924-929. doi: 10.1016/j.jbmt.2017.10.008. Epub 2017 Oct 25.
Clinical trial NCT06358183: Surgical Capacity in Zimbabwean Public Hospitals
Official title: Comprehensive Analysis of Emergency and Essential Surgical Capacity in Zimbabwean Public Hospitals: A National Cross-sectional Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Anesthesia
Keywords: Global surgery
Surgical capacity
Zimbabwe
Lead sponsor: Parirenyatwa Hospital
Sponsor class: OTHER
First posted: 2024-04-10
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: public hospitals in zimbabwe

Brief summary: This study aimed to understand how ready Zimbabwe's public hospitals are to perform essential surgeries, which are critical for treating a wide range of health issues from emergencies like car accidents to planned procedures such as childbirth by caesarean section. The researchers looked at hospitals across Zimbabwe to see what kind of surgery facilities, equipment, and specialists were available.

Detailed description: Abstract Background: Access to surgical care is an essential component of universal health coverage, but surgical capacity is lacking in many low- and middle-income countries. Surgical capacity in Zimbabwe, a lower-middle income country, is undocumented. The objective of this study was to assess surgical capacity in public hospitals in Zimbabwe.

Methods: A national hospital survey was performed in 2019 using a validated surgical situational analysis tool. the investigators included district, provincial and central hospitals in the public sector across all 10 provinces of Zimbabwe. Data was collected from key informants using an online survey. information gathered included an inventory of infrastructural components required to perform essential surgical services, a survey of healthcare workers involved in surgical care (the Surgical Anaesthetic and Obstetric workforce); a submission of the number of surgical procedures including bellwether procedures performed over the course of the last year and also surgical sundries and consumables required to perform surgical services.

Eligibility criteria: Inclusion Criteria:

* Hospitals were considered eligible if there was any major or minor surgical activity occurring in the facility

Exclusion Criteria:

* hospitals dedicated to a non-surgical pursuit
* private hospitals

Primary outcomes:
measure: Bellwether procedures
timeFrame: in 1 calendar year
measure: Procedures
timeFrame: in 1 calendar year
measure: SAO density
timeFrame: in 1 calendar year
measure: Infrastructure
timeFrame: in 1 calendar year
Secondary outcomes:
Other outcomes:
Locations:
city: Harare
country: Zimbabwe
facility: Parirenyatwa Hospital
Study officials:
affiliation: Parirenyatwa
name: Shingai Nyaguse-Chiurunge
role: STUDY_DIRECTOR
References:
Clinical trial NCT04527783: The Use of an Engineered Glove for the Assessment and Rehabilitation of Manual Dexterity in People With Stroke.
Official title: The Use of an Engineered Glove for the Assessment and Rehabilitation of Manual Dexterity in People With Stroke: a Pilot Randomized Control Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Hand Grasp
Lead sponsor: Fondazione Don Carlo Gnocchi Onlus
Sponsor class: OTHER
First posted: 2020-08-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stroke often results in impairments of upper extremity, including coordination deficits, reducing of force, weakness and changes in the kinetic and kinematic workspace of fingers with 75% of stroke survivors facing difficulties performing activities of daily living.

The ability to oppose the fingertip of the thumb to each fingertip of the same hand is the basis of grasping objects of various sizes and operating tools and assessing and improving distal upper extremity function is of primary goal in the rehabilitation of stroke survivors. Moreover, repetitive movement practice seems to be crucial for maximizing therapeutic benefits.

Recent studies, proposed an engineered glove to assess motor performance during finger-to-thumb opposition movements and to provide objective and reproducible measures.

The same tool can be integrated with Virtual Reality and serious games to provide repetitive practice of activities improving motivation and adherence with therapy.

the investigators developed a new integrated glove and virtual reality to facilitate the recovery of hand functionality.

The aim of this study is to investigate the feasibility of the engineered glove in the assessment and treatment of hand dysfunction in people with Stroke.


Eligibility criteria: Inclusion Criteria:

* a single stroke,
* some movement of the fingers,
* any technical and difficulties with wearing the glove on the paretic hand

Exclusion Criteria:

* visual or cognitive deficits that would prevent them for performing the task

Primary outcomes:
measure: Change in Box and Blocks Test
timeFrame: baseline- immediately after the intervention
Secondary outcomes:
measure: Change in 9-Hole Peg Test
timeFrame: baseline- immediately after the intervention
measure: Change in Manual Ability Measurement
timeFrame: baseline- immediately after the intervention
measure: Change in the instrumented indexes
timeFrame: baseline- immediately after the intervention
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02469883: A Study of Sinotecean on Tolerance and Pharmacokinetics
Official title: A Phase I Study of Sinotecean on Tolerance and Pharmacokinetics
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Cancer
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-06-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.


Eligibility criteria: Inclusion Criteria:

* late malignant tumor patients diagnosed with the pathological and/or cytological;
* lack of the standard treatment or treatment failure;
* 18-65years, ECOG:0-1,expected survival period \>3 months;
* main organs function is normal;
* signed and dated informed consent

Exclusion Criteria:

* participated in other clinical trials in four weeks;
* currently under other effective treatment;
* end of anti-tumor treatment within 4 weeks(end of Nitrosourea/Mitomycin within 6 weeks);
* AE ≥ Grade 2(according to NCI-CTC 4.0),except hair loss;
* with ischemic heart disease, heart failure, severe arrhythmia, cerebrovascular disease, asthma, severe infections, active peptic ulcer;
* urine protein: ++, and urinary in 24 hours \> 1.0g;
* uncontrolled primary or metastatic brain;
* have immunodeficiency history;
* according to the researcher's judgment,there are concomitant diseases which will seriously endanger the patients or obstruct the patients to complete the clinical trial;

Primary outcomes:
measure: Pharmacokinetic Assessments for Area Under Curve（AUC）
timeFrame: Day 1-2 Single Dose
measure: Pharmacokinetic Assessments for Cmax
timeFrame: Day 1-2 Single Dose
measure: Pharmacokinetic Assessments for Tmax
timeFrame: Day 1-2 Single Dose
Secondary outcomes:
measure: Objective Response Rate （ORR)
timeFrame: each 42 days up to intolerance the toxicity or progression of disease（PD） (up to 24 months)
measure: Maximum tolerated dose(MTD)
timeFrame: up to 24 months
measure: Dose-limiting toxicity(DLT)
timeFrame: up to 24 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
References:
Clinical trial NCT01548183: Text-message Program to Reduce Risky Sexual Behavior in Young Adult Female Emergency Department (ED) Patients
Official title: Mobile Phone Text-message Program to Reduce Risky Sexual Behavior in Young Females Discharged From the Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Education, Sex
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2012-03-08
Enrollment: 52
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The US preventative services task force (USPSTF) recommends behavioral counseling in the primary care setting for prevention of sexually transmitted diseases, however, screening and counseling rarely occur. Text messaging (TM) is increasingly being used as a tool to affect behavior change in patients, but its effect on patients that report at-risk sexual behavior in the emergency department (ED) is unknown. The investigators seek to assess the feasibility of ED-based screening of young adult females for at-risk sexual behavior and enrolling them in a 3 month trial using TM to deliver information and skill building to improve health behavior.


Eligibility criteria: Inclusion Criteria:

* Female
* Age 18-25 years
* AUDIT-C score \> 2
* (Drugs or alcohol prior to last sex OR No condom with last sex OR \> 1 partner in last 3 months)

Exclusion Criteria:

* No personal cell phone with SMS features
* Prisoner
* Pregnant or planning in next 3 months
* Current or past drug/alcohol treatment or psychiatric treatment

Primary outcomes:
measure: Sex without condom
timeFrame: 3 months after ED discharge
Secondary outcomes:
measure: Number of unprotected vaginal sexual encounters
timeFrame: 3 months post-ED discharge
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: UPMC Mercy Hospital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT05250583: Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis
Official title: Use of a Double Amniotic Membrane Inserted in a Ring of Umbilical Vessels with Wharton's Jelly, Tissues Treated by the AMTRIX Process, in the Treatment of Keratitis Resisting Healing Medical Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Keratitis
Lead sponsor: TBF Genie Tissulaire
Sponsor class: INDUSTRY
First posted: 2022-02-22
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this open, mono center trial is to assess the impact of the use of an amniotic membrane on the healing of a keratitis resistant to medical treatment.


Eligibility criteria: Inclusion Criteria:

* Male or female; age between 18 and 65 years.
* Patient with non-infectious keratitis resistant to medical treatment for more than 15 days or recurrent after healing treatment.
* Patient with quantitative and qualitative score for inflammatory ocular signs \> 20.
* Patient with Oxford grade \> 2.
* Informed and consenting patient with a relative or friend available to instill eye drops if necessary.
* Patient affiliated to a social security system or beneficiary of such a system.

Exclusion Criteria:

* Patient with active infectious keratitis (bacterial, parasitic or viral).
* Patient with allergy to Oxybuprocaine or Tetracaine eye drops, to ester type local anesthetics and to fluorescein.
* Current contact lens wear, including scleral lenses.
* NSAID eye drops and any drops containing preservatives.
* Antibiotic, anti-viral, anti-parasitic eye drops.
* Patient with identified causes for the keratitis for which discontinuation of medical treatment beneficial.
* Ocular surgery in the 3 months preceding the inclusion in the study.
* Monophtalmic patient.
* Person deprived of liberty by a judicial or administrative decision.
* Adult subjected to a legal protection measure or unable to express his/her consent.

Primary outcomes:
measure: Keratitis healing within 15 days after the beginning of the treatment
timeFrame: 15 days
Secondary outcomes:
measure: Stable or decreased score for inflammatory and clinical signs of the ocular surface
timeFrame: 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days
measure: Stabilisation or decrease of pain evaluated on visual analog scale
timeFrame: 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days
measure: Preservation of epithelialization
timeFrame: 15 days, 30 days, 45 days
measure: Change in eye dryness
timeFrame: 15 days, 30 days, 45 days
Other outcomes:
Locations:
city: Saint-Priest-en-Jarez
country: France
facility: CHU de Saint-Etienne Hôpital Nord
Study officials:
References:
Clinical trial NCT03478761: 24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry
Official title: 24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: 24-hydroxylase Deficiency
Keywords: CYP24A1 mutation
CYP24A1
24-hydroxylase deficiency
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2018-03-27
Enrollment: 600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 24-hydroxylase deficiency and CYP24A1 mutation patient

Brief summary: You are being asked to take part in this research registry because you or your family member is suspected to have a 24-hydroxylase deficiency.

Detailed description: In this registry we propose to establish and maintain a registry of suspected and confirmed patients with 24 hydroxylase deficiency in an effort to collect data for further investigation. This would be the first and only known registry of its kind. These resources would be made widely available to clinicians and research scientists within Mayo to stimulate advances in the diagnosis and treatment of patients with this disease.

Eligibility criteria: Inclusion Criteria:

Patients who have undergone genetic testing for a CYP24A1 mutation with at least 3 of the following:

* Urinary Stone Disease
* Nephrocalcinosis
* Metabolic Bone Disease
* Serum Calcium \>/= 9.6 mg/dL
* Parathyroid hormone (PTH) \< 30 pg/mL
* 1,25-dihydroxyvitamin D \> 40 pg/mL OR a family member of a patient who meets the above criteria

Exclusion Criteria:

Patients who have tested negative for a CYP24A1 mutation with an alternative diagnosis that might explain hypercalcemia/hypercalciuria/stone disease:

* Sarcoidosis
* Lymphoma
* Tuberculosis
* Fungal infections
* Excessive exogenous calcium or vitamin D intake

Primary outcomes:
measure: establish and maintain a registry of suspected and confirmed patients with 24 hydroxylase deficiency
timeFrame: yearly
Secondary outcomes:
measure: Improved understanding of symptoms and progression of this disease
timeFrame: yearly
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David Sas, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Peter Tebben, MD
role: STUDY_DIRECTOR
References: